<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02454075</url>
  </required_header>
  <id_info>
    <org_study_id>T-010</org_study_id>
    <secondary_id>11-DK-0114</secondary_id>
    <nct_id>NCT02454075</nct_id>
    <nct_alias>NCT01322542</nct_alias>
  </id_info>
  <brief_title>YF476 and Type II Gastric Carcinoids</brief_title>
  <official_title>A Pilot Trial of YF476, a Gastrin Antagonist, in Patients With Type II Gastric Carcinoids Associated With Zollinger-Ellison Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trio Medicines Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Trio Medicines Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate whether treatment with YF476 is safe and effective in reducing the
      size of type II gastric carcinoid tumours, or limiting the abnormal growth of gastric ECL
      cells, in patients with Zollinger-Ellison syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regression of gastric carcinoids and/or ECL cell hyperplasia defined by physical measurements taken during endoscopy</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Regression is defined as a 25% reduction in the size / number of endoscopically evident type II gastric carcinoids; or a reduction of 25% in the gastric ECL cell density.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in histological grade of gastric carcinoids/ECL cell hyperplasia defined by physical measurements taken during endoscopy</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Reduction in the histological grade of the carcinoids/hyperplasia when compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of gastrin and chromogranin A (CgA) biomarkers measured in blood samples</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Reduction in the levels of circulating gastrin and CgA biomarkers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control of gastric acid secretion assessed by changes in drug-controlled gastric acid analysis (acid control study)</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Assessed by changes in drug-controlled gastric acid analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in ECL cell-specific products assessed by quantitative PCR</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Assessed by quantitiative PCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in reflux/dyspepsia symptoms using the GERD-HRQL instrument</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Assessed by the GERD-HRQL instrument.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability by monitoring adverse events</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>The treatment is safe and well tolerated when added to existing treatments for ZES.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Zollinger-Ellison Syndrome</condition>
  <arm_group>
    <arm_group_label>Eligible patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose will be 100 mg YF476 once daily. When 6 patients have completed 12 weeks' treatment with that dose, it may be increased to 150 or 200 mg once daily. Patients will have type II gastric carcinoids and/or ECL cell hyperplasia/dysplasia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YF476</intervention_name>
    <description>Gastrin receptor antagonist</description>
    <arm_group_label>Eligible patients</arm_group_label>
    <other_name>Netazepide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Men; post-menopausal women; pre-menopausal women who have been sterilised by tubal
             ligation, hysterectomy or bilateral oophorectomy; or pre-menopausal women using one of
             the allowed methods of contraception: condom and spermicide or intra-uterine device.

          2. Patients with serum gastrin &gt;250 pg/mL.

          3. Hepatic function: AST and ALT ≤2.0 x ULN; total bilirubin ≤1.0 x ULN.

          4. Renal function: serum creatinine &lt;1.0 x ULN.

          5. Haematologic function: Hb ≥10.0 g/dL; WBC ≥3.5 x 10e9 /L; ANC ≥1.5 x 10e9 /L;
             platelets ≥100 x 10e9 /L.

          6. Coagulation parameters: INR or PT ≤1.0 x ULN; PTT ≤1.0 x ULN.

          7. Ability to communicate satisfactorily with the investigator and to participate in, and
             comply with the requirements of, the entire trial.

          8. Willingness to give fully-informed, written consent.

        Exclusion criteria:

          1. Patients under 18 years.

          2. Women who are pregnant, lactating or using a steroid contraceptive.

          3. Prior gastric resection or bypass.

          4. Planned gastrinoma resection during the study period.

          5. Patients on somatostatin analogues, except for those on therapy for &gt;6 months with
             stable or worsening carcinoids.

          6. Inability to tolerate endoscopy, or refusal of endoscopy.

          7. Physical findings, ECG (especially prolonged QTc interval &gt;450 msec), or laboratory
             values at the pre-trial screening assessment that could interfere with the objectives
             of the trial or the safety of the subject.

          8. Certain medicines and herbal remedies taken during the 7 days before visit 2.

          9. Participation in a trial of an IMP within the previous 28 days.

         10. Presence of drug or alcohol abuse.

         11. History or baseline findings of:

               -  type 1 diabetes mellitus;

               -  pancreatitis (baseline amylase and/or &gt;2.0 x ULN);

               -  hepatitis B, hepatitis C or HIV;

               -  malabsorption syndrome or inability to swallow or retain oral medicine;

               -  major surgery &lt;28 days prior to enrolment;

               -  ECOG performance staus &gt;2; or

               -  another cancer within 3 years except for basal carcinoma of the skin or cervical
                  carcinoma in-situ.

               -  Also, any clinically significant and uncontrolled major morbidity including but
                  not limited to; serious cardiac disease (unstable angina, s/p myocardial
                  infarction &lt;1 month); respiratory disease (advanced COPD or pulmonary fibrosis);
                  uncontrolled hypertension; or active systemic infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2015</study_first_submitted>
  <study_first_submitted_qc>May 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2015</study_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>YF476</keyword>
  <keyword>netazepide</keyword>
  <keyword>gastric carcinoids</keyword>
  <keyword>Zollinger-Ellison syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Zollinger-Ellison Syndrome</mesh_term>
    <mesh_term>Gastrinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

